---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012223"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:26:29.299650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ArriVent Q2 net loss $39.3M; cash $298.7M funds into 2026; firmonertinib data at WCLC

## Summary
- Net loss for six months ended June 30, 2024 was $39.3M, compared to $33.7M in prior year period.
- Cash and cash equivalents $298.7M as of June 30, 2024; expected to fund operations into 2026.
- R&D expenses $38.8M (up from $30.6M) due to increased headcount and firmonertinib clinical costs.
- Interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC to be presented at WCLC presidential symposium on Sept 9, 2024.
- Entered ADC collaboration with Alphamab to discover and develop novel ADCs.

## SEC filing metadata
- accession: 0001558370-24-012223
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000155837024012223/0001558370-24-012223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000155837024012223/avbp-20240814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012223
- JSON: https://secwatch.observer/filing/0001558370-24-012223.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.